MCL1 and diffuse large B-cell lymphoma: Dinaciclib, a pan-CDK inhibitor, has been shown to downregulate MCL1 leading to apoptosis induction and antitumor efficacy in DLBCL preclinical models (25) and clinical activity has been demonstrated in patients with relapsed/refractory chronic lymphocytic leukemia (CLL; ref. 26).